[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2019

April 2019 | 154 pages | ID: ACEB0B501C5EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2019, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline landscape.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Treatment includes analeptics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 6, 9, 11, 16, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Attention Deficit Hyperactivity Disorder (ADHD) - Overview
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Development
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment
Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development
Attention Deficit Hyperactivity Disorder (ADHD) - Drug Profiles
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products
Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by 4P-Pharma SAS, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals LLC, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioHealthonomics Inc, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cerecor Inc, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Ensysce Biosciences Inc, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc, H1 2019
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc, H1 2019

LIST OF FIGURES

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

COMPANIES MENTIONED

4P-Pharma SAS
Amarantus Bioscience Holdings Inc
APeT Holding BV
Arbor Pharmaceuticals LLC
BCWorld Pharm Co Ltd
BioHealthonomics Inc
Cerecor Inc
Cingulate Therapeutics LLC
Collegium Pharmaceutical Inc
Curemark LLC
DURECT Corp
Ensysce Biosciences Inc
Highland Therapeutics Inc
KemPharm Inc
leon-nanodrugs GmbH
Merck & Co Inc
Otsuka Holdings Co Ltd
Otsuka Pharmaceutical Co Ltd
P2D Inc
RespireRx Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Shenox Pharmaceuticals LLC
Shionogi & Co Ltd
SK Biopharmaceuticals Co Ltd
Sosei Heptares
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Tris Pharma Inc


More Publications